A recent collaborative study in Europe published in 2021 aimed to estimate the incidence of retinoblastoma, revealing a higher rate than previously reported. Through a comprehensive analysis of data from 24 countries, the research demonstrated an incidence rate of 1 in 13,915 live births, higher than earlier findings. Notably, the study highlighted the impact of improved treatments on higher survival rates, leading to an increase in familial retinoblastoma cases and subsequently elevating the overall incidence. The data indicated an evolving trend in the incidence of retinoblastoma in Europe, calling attention to the complex interplay between improved therapies and the genetic landscape of the disorder. The study sheds light on the evolving dynamics of retinoblastoma incidence and the influence of improved treatments on the genetic profile of affected populations.